A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single and Multiple Ascending Doses of FRTX-02 in Healthy Subjects and Subjects With Atopic Dermatitis
Sponsor: Fresh Tracks Therapeutics, Inc.
Terminated
Business Decision
This PHASE1 trial investigates Atopic Dermatitis Eczema and is currently terminated or withdrawn. Fresh Tracks Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)This is a randomized, placebo controlled, double blind study in healthy subjects and subjects with atopic dermatitis that is designed to assess the safety and tolerability of FRTX-02 capsules at single and multiple ascending doses.
Safety will be assessed through vital signs, ECG, adverse events and safety laboratory tests.
Pharmacokinetic and pharmacodynamic information will also be collected.
This is a randomized, placebo controlled, double blind study in healthy subjects and subjects with atopic dermatitis that is designed to assess the safety and tolerability of FRTX-02 capsules at single and multiple ascending doses.
Safety will be assessed through vital signs, ECG, adverse events and safety laboratory tests.
Pharmacokinetic and pharmacodynamic information will also be collected.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fresh Tracks Therapeutics, Inc.
- Innovaderm Research Inc.
- Syneos Health
For direct contact, visit the study record on ClinicalTrials.gov .